Literature DB >> 1486071

Topical ofloxacin compared with gentamicin in the treatment of external ocular infection. Ofloxacin Study Group.

A Gwon1.   

Abstract

In a double-masked, randomised, controlled study the effectiveness and safety of 0.3% ofloxacin solution were compared with those of 0.3% gentamicin ophthalmic solution in treating external bacterial ocular infections. The clinical improvement rate for patients treated with ofloxacin was 98% (51/52) and 92% (48/52) for those treated with gentamicin. Microbiological improvement was achieved in 78% (40/51) of the ofloxacin patients, compared with 67% (35/52) of the gentamicin group. Ofloxacin treatment eradicated or controlled 85% (86/101) of the Gram positive and 89% (17/19) of the Gram negative organisms cultured, compared with 83% (103/124) and 78% (29/37), respectively, after gentamicin treatment. None of these differences were statistically significant. The incidence of adverse effects attributable to ofloxacin treatment (3.2%) was less than that reported for gentamicin (7.1%). Ofloxacin proved to be an effective, safe, and comfortable therapy for external bacterial ocular infection.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1486071      PMCID: PMC504389          DOI: 10.1136/bjo.76.12.714

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  29 in total

1.  Comparison of antibiotic therapy in presumptive bacterial conjunctivitis.

Authors:  N Jarudi; B Golden; J Hoyme; M D Tyson; J G Harter
Journal:  Am J Ophthalmol       Date:  1975-05       Impact factor: 5.258

2.  Ofloxacin in human serum, urine, and tear film after topical application.

Authors:  L Borrmann; D D Tang-Liu; J Kann; J Nista; E T Lin; J Frank
Journal:  Cornea       Date:  1992-05       Impact factor: 2.651

3.  New "ofloxacin" type antibacterial agents. Incorporation of the spiro cyclopropyl group at N-1.

Authors:  J S Kiely; M C Schroeder; J C Sesnie
Journal:  J Med Chem       Date:  1988-10       Impact factor: 7.446

4.  In vitro comparison of A-56619, A-56620, amifloxacin, ciprofloxacin, enoxacin, norfloxacin, and ofloxacin against methicillin-resistant Staphylococcus aureus.

Authors:  S M Smith
Journal:  Antimicrob Agents Chemother       Date:  1986-02       Impact factor: 5.191

Review 5.  Mode of action, and in vitro and in vivo activities of the fluoroquinolones.

Authors:  P B Fernandes
Journal:  J Clin Pharmacol       Date:  1988-02       Impact factor: 3.126

6.  Comparison of ofloxacin, gentamicin, and tobramycin concentrations in tears and in vitro MICs for 90% of test organisms.

Authors:  J Richman; H Zolezio; D Tang-Liu
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

7.  The comparative in vitro activity of ofloxacin and selected ophthalmic antimicrobial agents against ocular bacterial isolates.

Authors:  M S Osato; H G Jensen; M D Trousdale; J A Bosso; L R Borrmann; J Frank; P Akers
Journal:  Am J Ophthalmol       Date:  1989-10-15       Impact factor: 5.258

8.  Topical fluoroquinolones: antimicrobial activity and in vitro corneal epithelial toxicity.

Authors:  P E Cutarelli; J H Lass; H M Lazarus; S C Putman; M R Jacobs
Journal:  Curr Eye Res       Date:  1991-06       Impact factor: 2.424

Review 9.  Ofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J P Monk; D M Campoli-Richards
Journal:  Drugs       Date:  1987-04       Impact factor: 9.546

10.  The comparative activity of twelve 4-quinolone antimicrobials against Haemophilus influenzae and Streptococcus pneumoniae.

Authors:  G L Ridgway; M D O'Hare; D Felmingham; R N Grüneberg
Journal:  Drugs Exp Clin Res       Date:  1985
View more
  10 in total

1.  Penetration of topical, oral, and combined administered ofloxacin into the subretinal fluid.

Authors:  O Cekiç; C Batman; U Yasar; Y Totan; N E Basci; A Bozkurt; O Zilelioglu; S O Kayaalp
Journal:  Br J Ophthalmol       Date:  1999-10       Impact factor: 4.638

Review 2.  Interventions for chronic blepharitis.

Authors:  Kristina Lindsley; Sueko Matsumura; Elham Hatef; Esen K Akpek
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

Review 3.  Current approach to postoperative endophthalmitis.

Authors:  G Sunaric-Mégevand; C J Pournaras
Journal:  Br J Ophthalmol       Date:  1997-11       Impact factor: 4.638

4.  Safety and tolerability of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis: data from six clinical and phase I safety studies.

Authors:  Timothy L Comstock; Michael R Paterno; Heleen H Decory; Dale W Usner
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

Review 5.  Treatment of ocular infections with topical antibacterials.

Authors:  J P Leeming
Journal:  Clin Pharmacokinet       Date:  1999-11       Impact factor: 6.447

Review 6.  Infectious endophthalmitis after cataract surgery.

Authors:  D S Hughes; R J Hill
Journal:  Br J Ophthalmol       Date:  1994-03       Impact factor: 4.638

7.  Acute infectious conjunctivitis in childhood.

Authors:  R Chawla; J D Kellner; W F Astle
Journal:  Paediatr Child Health       Date:  2001-07       Impact factor: 2.253

Review 8.  Pharmacokinetic considerations in the treatment of bacterial keratitis.

Authors:  M C Callegan; R J O'Callaghan; J M Hill
Journal:  Clin Pharmacokinet       Date:  1994-08       Impact factor: 6.447

9.  Improved corneal bioavailability of ofloxacin: biodegradable microsphere-loaded ion-activated in situ gel delivery system.

Authors:  Elshaimaa G Sayed; Amal K Hussein; Khaled A Khaled; Osama A A Ahmed
Journal:  Drug Des Devel Ther       Date:  2015-03-10       Impact factor: 4.162

10.  The effectiveness of a three-step sterilization method for Goldmann tonometer prism: A cross-sectional study.

Authors:  Jinping Hu; Jun Liu; Jingting Xia; Jingyu Yan; Zheng Liu; Dan Ma
Journal:  Indian J Ophthalmol       Date:  2022-01       Impact factor: 1.848

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.